A method is fit for purpose when its required performance is written down first and proven afterwards, in the shared vocabulary of ICH Q14 and Q2(R2)
How an analytical target profile, risk assessment and designed experiments lead to a method operable design region, what validation must show, and how detection and quantitation limits are estimated.
Status. EUTECNIQ has no laboratory, methods or validation data; examples use stated, illustrative parameters. ICH Q2(R2) and Q14 are written for drugs; for dietary supplements, 21 CFR Part 111 requires scientifically valid methods without prescribing a protocol.
Zhu et al., J Chromatogr A 1996; NIST Certificate of Analysis, SRM 3247 (2021); ICH Q2(R2) and Q14, adopted November 1, 2023 (FDA final guidance, March 2024).
Method development decides what a laboratory can prove about an ingredient, so it is planned from the decision the result must support
Text version: what EUTECNIQ and partners would do
- Write an analytical target profile for each marker assay before development
- Map critical parameters with designed experiments and retention models
- Validate, transfer and monitor methods over their life cycle
- Use certified reference materials to check accuracy
- Provide accredited testing and orthogonal confirmation until EUTECNIQ's laboratory exists
- Supply compendial and certified reference materials
- Run interlaboratory (reproducibility) studies
- Any validated method, accreditation or data of its own
- That the resolution map predicts a real column
- That ICH drug guidelines are legally binding for supplements
- A validated method≠a correct specification
- Validation at one time point≠ongoing performance verification
- A modeled resolution map≠resolution measured on the column
- An estimated quantitation limit≠a limit confirmed with samples at that level
- A high r²≠an adequate calibration model
The catalog of methods by question (identity, purity, contaminants, solid state, particles, microbiology) is on Analytical characterization. This page covers how a method is developed and validated.
Explanation, details and sources
A botanical release decision rests on a handful of numbers: identity, marker content, contaminants. Each comes from a method whose bias, precision, selectivity and range must be good enough for the specification it checks. ICH Q14 describes how to develop such a method; ICH Q2(R2) describes how to show that it works.
In the enhanced approach, performance criteria come first, parameters are mapped by experiment, and the method then runs inside a proven region
Text version: the seven steps, ICH Q14 glossary definitions and the minimal and enhanced approaches
- Analytical target profileIntended purpose, attribute, performance criteria
- Technology choiceThe ATP drives the technique; several may qualify
- Risk assessmentWhich parameters could affect performance (ICH Q9 tools)
- Experiments and modelsUnivariate PARs or multivariate MODRs
- Control strategySet points, ranges and system suitability test
- ValidationICH Q2(R2) performance characteristics
- Routine use and changeOngoing monitoring; established conditions (ICH Q12)
- Analytical target profile (ATP)
- "A prospective summary of the performance characteristics describing the intended purpose and the anticipated performance criteria of an analytical measurement."
- Method operable design region (MODR)
- "A combination of analytical procedure parameter ranges within which the analytical procedure performance criteria are fulfilled and the quality of the measured result is assured."
- Proven acceptable range (PAR)
- "A characterised range of an analytical procedure parameter for which operation within this range, while keeping other parameters constant, will result in an analytical measurement meeting relevant performance criteria."
- Analytical procedure control strategy
- "A planned set of controls derived from current analytical procedure understanding that ensures the analytical procedure performance and the quality of the measured result."
- System suitability test (SST)
- Tests "developed and used to verify that the measurement system and the analytical operations associated with the analytical procedure are fit for the intended purpose and increase the detectability of unacceptable performance."
- Established conditions (ECs)
- "legally binding information considered necessary to assure product quality" (ICH Q12); changing them requires a regulatory submission.
ICH Q14 Analytical Procedure Development, final version adopted November 1, 2023, Glossary. FDA published Q14 and Q2(R2) as final guidances (Federal Register, March 7, 2024; docket FDA-2022-D-1503). Final guidance
The minimal approach is still acceptable; the enhanced approach adds the ATP, risk assessment, multivariate studies and a control strategy with ranges
| Element | Minimal | Enhanced |
|---|---|---|
| Attributes to test, technology, performance studies, documented procedure and control strategy | Required | Required |
| Analytical target profile | Optional | Documents the anticipated performance criteria |
| Risk assessment and prior knowledge to find influential parameters | Not among the minimal elements | Included |
| Uni- or multivariate experiments and modeling of parameter ranges and interactions | Not among the minimal elements | Included |
| Ranges in the control strategy | Not among the minimal elements (a univariate study can still establish a PAR) | Set points and ranges, which "could include" PARs and MODRs; "Moving within an approved PAR or MODR does not require regulatory notification" |
ICH Q14, sections 2.1 and 5.2. Formal submission of an ATP is optional (section 3).
Explanation, details and sources
ICH Q14 keeps the minimal (traditional) approach acceptable and adds elements that build more understanding and allow more flexibility after approval. USP ⟨1220⟩ describes the same life cycle in three stages.
Drug guidelines, compendial chapters and the supplement regulation each set a different part of the bar
eCFR, 21 CFR 111.75 and 111.320 (accessed October 23, 2026); ICH Q14 and Q2(R2) (November 1, 2023); USP ⟨1220⟩ official date per USP announcement reported by Pharmaceutical Technology (September 2021); USP ⟨1225⟩ revision per ECA Academy news, November 13, 2025 (secondary report; whether the revision has become official was not verified); USP chapter titles per USP presentation by H. Pappa; USP ⟨621⟩ Stage 4 harmonization notice; Brown P, et al. J AOAC Int. 2016, SMPR 2016.003.
Explanation, details and sources
For dietary supplements the binding requirement is 21 CFR Part 111. ICH guidelines and USP chapters are the most detailed public statements of good practice, and EUTECNIQ would apply them as its internal standard (proposal).
| Document | What it covers | Status (October 2026) |
|---|---|---|
| 21 CFR 111.320 and 111.75 | Methods must be "appropriate for their intended use" (111.320(a)); a "scientifically valid method for each established specification" (111.320(b)); tests "are appropriate, scientifically valid methods" (111.75(h)(1)); at least one identity test for each dietary ingredient (111.75(a)(1)(i)) | Regulation in force |
| ICH Q14, Analytical Procedure Development | Minimal and enhanced development, ATP, risk management, robustness, PAR and MODR, control strategy, life-cycle changes, multivariate procedures | Final, adopted November 1, 2023 |
| ICH Q2(R2), Validation of Analytical Procedures | Performance characteristics, validation tests and reportable ranges; lower range limits (DL, QL) | Final, adopted November 1, 2023 |
| USP ⟨1220⟩ Analytical Procedure Life Cycle | Stage 1 procedure design; stage 2 procedure performance qualification; stage 3 ongoing procedure performance verification | Official May 1, 2022 |
| USP ⟨1225⟩ Validation of Compendial Procedures | Validation characteristics for compendial methods | Revision proposed PF 51(6) proposed renaming it "Validation of Analytical Procedures" and aligning it with Q2(R2); comments closed January 31, 2026 |
| USP ⟨1226⟩ Verification of Compendial Procedures | Showing that a compendial method works in a given laboratory and matrix | In USP–NF |
| USP ⟨1224⟩ Transfer of Analytical Procedures | Moving a validated method between laboratories | In USP–NF |
| USP ⟨621⟩ Chromatography | Definitions (resolution, plate number, symmetry factor), system suitability, allowed adjustments | Harmonized text official December 1, 2022 |
| AOAC Standard Method Performance Requirements (SMPRs) | "the minimum recommended performance characteristics to be used during the evaluation of a method"; for example SMPR 2016.003 for curcuminoids | Voluntary consensus standard |
Identity testing needs specificity, an assay needs accuracy, precision and range, and a limit test needs a detection limit
Text version: ICH Q2(R2) Tables 1 and 2
Typical performance characteristics by measured attribute (ICH Q2(R2) Table 1)
| Characteristic | Identity | Impurity, quantitative | Impurity, limit test | Assay |
|---|---|---|---|---|
| Specificity test | + | + | + | + |
| Range: response (calibration model) | − | + | − | + |
| Range: lower range limit | − | QL (DL in some complex cases) | DL | − |
| Accuracy test | − | + | − | + |
| Repeatability test | − | + | − | + |
| Intermediate precision test | − | + | − | + |
ICH Q2(R2), Table 1. Accuracy and precision may be evaluated in a combined approach; intermediate precision need not be studied separately when reproducibility data allow it to be derived; lack of specificity of one procedure "should be compensated by one or more other supporting analytical procedures".
Reportable ranges for common uses (ICH Q2(R2) Table 2)
| Use | Low end | High end |
|---|---|---|
| Assay of a product | 80% of declared content or of the lower specification criterion | 120% of declared content or of the upper specification criterion |
| Content uniformity | 70% of declared content | 130% of declared content |
| Impurity | Reporting threshold | 120% of the specification criterion |
| Purity (area %) | 80% of the lower specification criterion | Upper specification criterion or 100% |
ICH Q2(R2), Table 2 (selected rows). For linearity, "a minimum of five concentrations appropriately distributed across the range is recommended" (section 3.2.2.1).
Explanation, details and sources
ICH Q2(R2) Table 1 lists the typical characteristics for each measured quality attribute. Robustness moved to development (ICH Q14). Table 2 sets the reportable ranges that validation must cover.
For a quantified ginkgo extract, the ATP would tie each performance criterion to the width of the marker range it must police
Format: ICH Q14 Annex A, example 13.1.1 (its own ATP sets, for instance, 80–120% recovery for impurities at 0.1% and an SST resolution of at least 2.0 for the critical pair). Marker ranges: EMA/HMPC/CHMP/CVMP/287539/2005. Reference material: NIST SRM 3247 certificate (2021). Criteria marked illustrative are EUTECNIQ proposals.
Explanation, details and sources
The format follows the worked example in ICH Q14 Annex A; the criteria are EUTECNIQ's illustrative proposal, not a compendial requirement. The marker ranges are from the EMA's quantified ginkgo example (see Purification & standardization).
| Element | Proposed content | Rationale |
|---|---|---|
| Intended purpose | Quantify ginkgolides A, B and C (sum) and bilobalide in ginkgo leaf dry extract for release and stability testing | Quantified extract: content must stay within 2.8–3.4% and 2.6–3.2% |
| Reportable range | At least 2.24–4.08% (ginkgolides) and 2.08–3.84% (bilobalide) | ICH Q2(R2) Table 2 assay row: 80% of the lower to 120% of the upper criterion (computed) |
| Accuracy | Mean recovery within ±3% of the certified value of a ginkgo extract reference material | Each range is about ±10% of its midpoint, so bias must use only a fraction of it illustrative |
| Precision | Intermediate precision RSD ≤ 3% | Keeps lot decisions near the limits from being dominated by measurement noise illustrative |
| Specificity | No interference from other terpene lactones (for example ginkgolide J) or matrix at the marker retention times; orthogonal confirmation by LC-MS during development | Ginkgolide J is certified separately in NIST SRM 3247 and must be resolved from the summed markers |
Gradient time and column temperature together move the critical pair, and the MODR is the region where every pair is resolved and the run is short enough
b = SΔC t0tG tR = t0blog[2.3kib(1 − tDt0ki) + 1] + t0 + tD
w = 4t0(1 + ke)√N, ke = 12.3b + 1/ki
Drag to rotate, or use the buttons; the top view (⊤) shows the MODR as a map. The trough is the C/D selectivity reversal.
At the default settings about 35% of the explored region is inside the MODR; the highest critical-pair resolution within a 25 min run is about 3.7, near a 21 min gradient at 36 °C.
Show the illustrative analyte parameters
| Constituent | log10 kw at 25 °C | B (K) | S |
|---|---|---|---|
| A | 2.30 | 850 | 4.1 |
| B | 2.38 | 980 | 4.5 |
| C | 2.98 | 800 | 4.8 |
| D | 3.02 | 1200 | 4.6 |
| E | 3.70 | 1050 | 5.4 |
Values were chosen to produce a realistic critical-pair change and one selectivity reversal. They are not measurements of any compound.
Method, assumptions and limits
- What it calculates
- Retention times and peak widths of five constituents in a linear gradient, the minimum resolution between adjacent peaks (the critical pair), the last retention time, and the region of gradient time and temperature where all pairs meet the required resolution and the run ends before the time limit.
- Equations
- log k = log kw − S·C; b = SΔC t0/tG; tR = (t0/b) log10[ln10·kib(1 − tD/(t0ki)) + 1] + t0 + tD (2.303 in the source is ln 10); ke = 1/(ln10·b + 1/ki); w = 4t0(1 + ke)/√N; log10 kw = A + B/T. A constituent with kit0 ≤ tD elutes before the gradient arrives, tR = t0(1 + ki).
- Variables and units
- tG, t0 = 1.5, tD, tR, w in minutes; C volume fraction of organic solvent, 0.05 to 0.95 (ΔC = 0.9); T in kelvin inside the van 't Hoff term; N plates; S and B per constituent.
- Assumptions
- Linear LSS behavior; S independent of temperature; constant enthalpy (linear van 't Hoff plot); the same plate number for every peak; no gradient compression; Gaussian peaks; every constituent elutes before the gradient ends (points where one does not are excluded from the MODR).
- Valid range
- The slider and map ranges. Retention can deviate from LSS and van 't Hoff linearity; Tanase et al. (2019) attribute nonlinear van 't Hoff behavior largely to multiple retention mechanisms.
- What it does not establish
- A method for any real extract; robustness to pH, column lot or instrument; peak purity. ICH Q14 requires the routine operating point to be covered by validation data, and model predictions must be confirmed experimentally.
- How practitioners build such maps
- Zhu et al. (1996) showed that four initial runs (two gradient times × two temperatures) allow retention to be predicted over both variables; Dolan et al. (1998) used resolution maps from such runs to optimize 14 samples.
- Verification
- The Python reference does not use the closed-form equation: it integrates the band-migration equation dz/dt = (L/t0)/(1 + k(C(z, t))) through the dwell volume and the gradient (scipy.integrate.solve_ivp) and compares resolution, retention and the MODR share with the page (
tests/numerics/ref/technologies-analytical-method-development.py).
Explanation, details and sources
Five illustrative constituents (A–E) are separated by a 5–95% organic gradient. Their retention follows the linear-solvent-strength model, and temperature enters through a van 't Hoff term. Peaks C and D swap order near 55 °C, so resolution collapses along a ridge; at low temperature the A/B pair becomes critical. The amber region meets both criteria.
Detection and quantitation limits estimated from a calibration line are only as good as the standards near the limit
sy/x = √(Σei²/(n − 2)) sa = sy/x√(1/n + x̄²/Σ(xi − x̄)²)
| # | Concentration (µg/mL) | Peak area |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| 4 | ||
| 5 | ||
| 6 | ||
| 7 |
Method, assumptions and limits
- What it calculates
- An ordinary least-squares line through the standards, r², the residual standard deviation, the standard error of the intercept, DL and QL from each, and the largest relative error when each standard is read back through the line.
- Equations
- S = Σ(x − x̄)(y − ȳ)/Σ(x − x̄)²; intercept a = ȳ − S x̄; sy/x = √(Σ residual²/(n − 2)); sa = sy/x√(1/n + x̄²/Σ(x − x̄)²); DL = 3.3σ/S; QL = 10σ/S.
- Tool simplification
- ICH Q2(R2) refers to "the standard deviation of y-intercepts of the regression lines" (several lines). With one line, the standard error of its intercept is used here as a single-curve estimate and labeled as such.
- Assumptions
- Constant variance and a straight line. Neither holds for the "wide range" and "saturation" presets, which is the point of them.
- Valid range
- At least three points with different concentrations and a positive slope; non-numeric entries are ignored. ICH recommends at least five concentrations for linearity.
- What it does not establish
- That the limits are achieved. ICH Q2(R2) section 3.2.3.5: an estimated QL "should be subsequently validated by the analysis of a suitable number of samples known to be near or at the QL".
- Verification
- The Python reference uses scipy.stats.linregress (slope, intercept, r, intercept standard error) and numpy, in
tests/numerics/ref/technologies-analytical-method-development.py.
Explanation, details and sources
ICH Q2(R2) allows DL = 3.3σ/S and QL = 10σ/S, with σ taken from the blank, the residual standard deviation of the regression line, or the standard deviation of y-intercepts of regression lines, and asks that the calibration be evaluated with samples near the limits. Edit the standards or pick a preset to see why.
A result on a certified reference material shows bias only when its difference exceeds the combined uncertainty
UΔ = 2 √(um2 + uCRM2)
Data table
| Analyte | Certified value | U95 | U95 / value |
|---|---|---|---|
| Quercetin | 45.1 | 4.6 | 10.2% |
| Kaempferol | 40.8 | 3.0 | 7.4% |
| Isorhamnetin | 10.8 | 1.3 | 12.0% |
| Total aglycones | 96.8 | 8.3 | 8.6% |
| Ginkgolide A | 11.6 | 1.7 | 14.7% |
| Ginkgolide B | 5.92 | 0.45 | 7.6% |
| Ginkgolide C | 12.4 | 1.4 | 11.3% |
| Ginkgolide J | 3.9 | 1.5 | 38.5% |
| Bilobalide | 28.5 | 2.1 | 7.4% |
| Total terpene lactones | 62.4 | 5.7 | 9.1% |
Method, assumptions and limits
What it calculates. Whether a laboratory's mean result on SRM 3247 differs significantly from the certified value, following ERM Application Note 1, and the apparent recovery (result / certified value).
Equations. Δm = |cm − cCRM|; uCRM = U95 / 2 (the certificate says to treat the certified value as normal with standard deviation U95/2); um = s/√n; UΔ = 2√(um2 + uCRM2). If Δm ≤ UΔ there is no significant difference.
Assumptions and limits. Taking um as the standard deviation of the mean, as in the note's worked example, ignores other uncertainty components (calibration, sample preparation, day-to-day effects), which would widen UΔ. Values are on a dry-mass basis. Agreement on one reference material does not validate a method for other matrices.
References. Linsinger T. ERM Application Note 1: Comparison of a measurement result with the certified value. European Commission JRC-IRMM; 2010. NIST SRM 3247 certificate (2021). Verification. Independent reference in tests/numerics/ref/ana_crm.py.
The certified values themselves carry 7.4% to 38.5% expanded uncertainty, so a recovery of 90% can still agree with the certificate while a tighter result shows bias.
Explanation, details and sources
A certified reference material (CRM) checks trueness: the laboratory measures it like a sample and compares the result with the certificate. ERM Application Note 1 combines the uncertainty of the result with that of the certified value, so a precise result that is slightly off can show significant bias while an imprecise one cannot. For SRM 3247, NIST certifies flavonoid aglycones (after hydrolysis of glycosides) and terpene lactones on a dry-mass basis; its certification is valid until 30 October 2029.
National Institute of Standards and Technology. Certificate of Analysis, Standard Reference Material 3247, Ginkgo biloba (Extract). Issued February 10, 2021. Linsinger T. ERM Application Note 1. European Commission JRC-IRMM; January 2010.
A method keeps its validated performance only if every run passes system suitability and its results are monitored over time
Text version: system suitability parameters and what each protects
| Parameter | Definition (USP ⟨621⟩) | What it protects |
|---|---|---|
| Resolution | Rs = 1.18(tR2 − tR1)/(Wh1 + Wh2) | Specificity of the critical pair (ICH Q14's example sets Rs ≥ 2.0) |
| Plate number | N = 5.54(tR/Wh)², from isocratic or isothermal data | Column efficiency, hence peak width and resolution |
| Symmetry (tailing) factor | AS = W0.05/(2d); 0.8–1.8 unless the monograph states otherwise | Integration accuracy and resolution |
| System repeatability | %RSD of replicate injections (at least three) | Precision of the reported result |
| Sensitivity | Signal-to-noise; the QL (S/N 10) at or below the reporting threshold | The lower end of the range |
USP ⟨621⟩ Chromatography, harmonized Stage 4 text official December 1, 2022 (definitions and system suitability); ICH Q14 section 6 and Annex A, Table 2.
Explanation, details and sources
The SST is part of the procedure, and "no sample analysis is acceptable unless the suitability of the system has been demonstrated" (USP ⟨621⟩). ICH Q14 adds that SST criteria should be derived from the method's performance criteria.
Plotting every run's control-sample result turns system suitability into trend detection: a small sustained shift trips the run rules long before any single result fails.
Explanation, details and sources
ICH Q14 treats the analytical procedure as a life cycle in which performance is monitored during routine use. A control chart of a stable control sample is one common way to do that; the zone rules flag one point beyond 3σ, two of three beyond 2σ, four of five beyond 1σ or eight in a row on one side, and the trend rule flags six points rising or falling. The data here are simulated, not EUTECNIQ results.
How instrument results, control-chart data and approvals would be kept attributable and auditable (21 CFR Part 11, ALCOA+) and carried onto a certificate of analysis: digital laboratory. Process capability and the full Six Sigma toolkit: quality and Six Sigma.
Need a marker assay that will hold up in an audit?
Share the botanical, the markers and the specification. EUTECNIQ would propose an ATP, a development plan and the validation evidence it would generate with partners.